Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)

NCT04571944 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Delirium

Interventions

DRUG: Suvorexant
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC